Categories: HospitalsNews

Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023

SPARTA, N.J., April 25, 2024 /PRNewswire/ — Bantec, Inc. (OTCPINK: BANT) (“Bantec” or the “Company”),  a product and services company, increased sales, and profits, through its Howco Distributing Co.  subsidiary (“Howco”), from first quarter 2023 to first quarter 2024.

Michael Bannon, Bantec’s Chairman and CEO stated: “Howco is currently in a growth spurt as demand continues to grow for our products and services. Additional purchase orders are coming in almost daily.”

“We reported $955,734 in Sales in Q1 2024 as opposed to Sales of $ 606,166 in Q1 2023. We reported a Gross Profit of $147,547.00 in Q1 2024 as opposed to a Gross Profit of $94,950 in Q1 2023. Both sales and profits increased over 50% from Q1 2023 to Q1 2024. The increased order inflow and growing financials, have opened doors to purchase order financing discussions, building a roadmap for more rapid growth”  continued Michael Bannon, Bantec’s Chairman and CEO. Look for further corporate development updates.

About Bantec 

Bantec, Inc. is a product and service company targeting the United States Government, state governments, municipalities, hospitals, universities, manufacturers, and other building owners. Bantec also provides product procurement, distribution, and logistics services through its wholly owned subsidiary, Howco Distributing Co., to the United States Department of Defense and Defense Logistics Agency. The Company established Bantec Sanitizing in fiscal year 2021, which offers sanitizing products and equipment through its website bantec.store. The Company has operations based in Sparta, New Jersey and Vancouver, Washington. The Company continues to seek strategic acquisitions and partnerships that offer it an opportunity to grow sales and profit.

Forward-Looking Statements 

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others.  These forward-looking statements may include projections of matters that affect revenue, operating expenses, projections of growth; and assumptions relating to the foregoing. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2023 that the Company filed with the SEC. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. 

Contacts:   
Michael Bannon
Chairman & CEO
Stockholders@Bantecinvestorrelations.com
(203) 220-2296

View original content:https://www.prnewswire.com/news-releases/bantec-reports-an-over-50-percent-increase-in-sales-and-profits-in-q1-2024-from-q1-2023-302126589.html

SOURCE Bantec, Inc.

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

3 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

6 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

6 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

6 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

6 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

6 hours ago